For an article about patient-advocacy groups that mobilized to expedite access to Relyvrio, a powdered drug designed for ALS treatment. The piece sheds light on the broader consequences of hasty FDA approvals. Published in the print edition of the June 26, 2023 issue of the New Yorker.